Janux is a clinical-stage company developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patientβs healthy tissue. Janux is using its platform masking technology to engineer novel drug candidates that are designed to overcome the traditional T cell engager toxicity and efficacy limitations. Janux is proud to have earned a ππ«πππ ππ₯πππ ππ¨ ππ¨π«π€ πππ«ππ’ππ’ππππ’π¨π§β’ in 2024.